Methotrexate intoxication: the Pharmaceutical Care process reveals a critical error
- PMID: 21463347
- DOI: 10.1111/j.1365-2710.2011.01263.x
Methotrexate intoxication: the Pharmaceutical Care process reveals a critical error
Abstract
What is known and objectives: Intoxication with oral low-dose methotrexate (MTX) is a well-known and frequent problem, which is often discovered accidently. The major reason is error in the frequency of dosing, mostly of daily instead of weekly intake. We report a case where the critical error was discovered by the community pharmacist during the routine implementation of the Pharmaceutical Care process SOAP while dispensing a new prescription for the patient.
Details of the case: A 78-year-old widow went to her regular community pharmacy to pick up a prescription for oral mucositis. The evaluation of the case by the pharmacist using the SOAP (an acronym for Subjective, Objective, Assessment and Plan) note method revealed the underlying oral low-dose MTX intoxication which led to hospitalization a few days later. The incorrect interpretation of the required dose had arisen from the written instructions for use and led to the erroneous intake of MTX daily (instead of weekly). We interviewed the patient at her home 2months after discharge. She explained that her continued intake of MTX in spite of manifest adverse effects was because of a profound conviction that she was doing right. Her confidence in physicians remained unchanged after the incident, but she would now refuse to take MTX.
What is new and conclusion: The reasons for the intoxication were not discovered accidently but by the routine use of the Pharmaceutical Care process SOAP by the community pharmacist. We describe three main errors that might have been avoided and provide solutions for physicians, pharmacists, manufacturers and patients, to reduce such risks. Our case highlights the dangers of teleconsultation, the crucial role of Pharmaceutical Care provided by community pharmacists and the continued need to supply advice to patients being prescribed low-dose MTX. The fact that a patient has had a previous and successful experience with a similar treatment should not deter health professionals from verifying a patient's understanding via questions and feedback.
© 2011 Blackwell Publishing Ltd.
Similar articles
-
Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.J Manag Care Pharm. 2014 Feb;20(2):194-200. doi: 10.18553/jmcp.2014.20.2.194. J Manag Care Pharm. 2014. PMID: 24456321 Free PMC article.
-
Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis.Am J Health Syst Pharm. 2008 Nov 15;65(22):2117-21. doi: 10.2146/ajhp070676. Am J Health Syst Pharm. 2008. PMID: 18997139
-
Short-term methotrexate therapy in psoriasis: a study of 197 patients.Int J Dermatol. 2002 Jul;41(7):444-8. doi: 10.1046/j.1365-4362.2002.01530.x. Int J Dermatol. 2002. PMID: 12121564
-
Community pharmacy practice in China: past, present and future.Int J Clin Pharm. 2013 Aug;35(4):520-8. doi: 10.1007/s11096-013-9789-5. Epub 2013 May 10. Int J Clin Pharm. 2013. PMID: 23661172 Review.
-
Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?Am J Clin Dermatol. 2005;6(6):357-63. doi: 10.2165/00128071-200506060-00003. Am J Clin Dermatol. 2005. PMID: 16343024 Review.
Cited by
-
Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases.J Clin Med. 2018 Dec 25;8(1):21. doi: 10.3390/jcm8010021. J Clin Med. 2018. PMID: 30585183 Free PMC article. Review.
-
Comment on: "Methotrexate Cutaneous Ulceration: A Systematic Review of Cases".Am J Clin Dermatol. 2023 May;24(3):487-489. doi: 10.1007/s40257-023-00773-9. Epub 2023 Apr 17. Am J Clin Dermatol. 2023. PMID: 37062793 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials